Evidence map›Paper›PMID 39058907›Full record

ReviewBioEssays : news and reviews in molecular, cellular and developmental biology2024

Childhood B cell leukemia: Intercepting the paths to progression.

Cesar Cobaleda, Carolina Vicente-Dueñas, Kim E Nichols, Isidro Sanchez-Garcia

Abstract readReview
In one paragraph

Review in BioEssays : news and reviews in molecular, cellular and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cesar CobaledaImmune System Development and Function Unit, Centro de Biología Molecular Severo Ochoa (CBM, CSIC-UAM), Madrid, Spain.
Carolina Vicente-DueñasInstitute for Biomedical Research of Salamanca (IBSAL), Department of Pediatrics, Hospital Universitario de Salamanca, Salamanca, Spain.ORCID 0000-0002-5401-8295
Kim E NicholsDivision of Cancer Predisposition, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Isidro Sanchez-GarciaInstitute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0001-6989-9905

Funding

Pathogenesis of ETV6-Related Acute Lymphoblastic LeukemiaR01CA241452 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI NICHOLS, KIM ERIKA · 2020 to 2025
$2.6M
JAK inhibition as a novel treatment for hemophagocytic lymphohistiocytosisR21AI113490 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI NICHOLS, KIM ERIKA · 2014 to 2015
$490k
American Lebanese Syrian Associated Charities (ALSAC) R01CA241452Banco de SantanderCures Within ReachEuropean Union (European Regional Development Fund (ERDF)/European Social Fund (ESF))FEDERFundación Científica de la Asociación Española contra el Cáncer PRYCO211305SANCFundación Ramón ArecesFundación Síndrome de Wolf-Hirschhorn o 4p-Fundacion Unoentrecienmil (CUNINA and CUNINA-2 projects)Histiocytosis AssociationInstituto de Salud Carlos III (ISCIII)/ FEDER PI22/00379Junta de Castilla y León CSI001U16Junta de Castilla y León CSI016P23Junta de Castilla y León CSI144P20Junta de Castilla y León CSI234P18Junta de Castilla y León UIC-017MCIU/AEI/FEDER PID2021-122185OB-I00MCIU/AEI/FEDER RTI2018-093314-B-I00MINECO/FEDER: SAF2015-64420-RMinisterio de Ciencia e Innovación/AEI/FEDER PID2021-122787OB-I00National Institute of Allergy and Infectious DiseasesNCI NIH HHS R01 CA241452NCI NIH HHS R21AI113490NIAID NIH HHS R21 AI113490TRANSCAN2023-1858-066- REACTION Project
6 · The paper itself

Abstract

B-cell Acute Lymphoblastic Leukemia (B-ALL) is the most common pediatric cancer, arising most often in children aged 2-5 years. This distinctive age distribution hints at an association between B-ALL development and disrupted immune system function during a susceptible period during childhood, possibly triggered by early exposure to infection. While cure rates for childhood B-ALL surpass 90% in high-income nations, survivors suffer from diminished quality of life due to the side effects of treatment. Consequently, understanding the origins and evolution of B-ALL, and how to prevent this prevalent childhood cancer, is paramount to alleviate this substantial health burden. This article provides an overview of our current understanding of the etiology of childhood B-ALL and explores how this knowledge can inform preventive strategies.

Indexed as

Disease ProgressionChildChild, PreschoolHumansLeukemia, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphomaacutechildhooddelay‐exposuregenetic susceptibilityinfectionleukemiamurine modelspreleukemic cells

Identifiers

PMID39058907
PMCPMC11864036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.